Recent studies in children with MIS-C have also highlighted the significantly higher levels of IL-1 receptor antagonist, IL-1β, IL-8, IL-10, IL-6, IL-27, and TNF-α in patients with MIS-C compared to health control (18, 19). This evidence concerns the gene IL1B and COVID-19–associated multisystem inflammatory syndrome in children.